Notably, M2 macrophages drive trastuzumab sensitivity by releasing immunosuppressive cytokines like interleukin-10 (IL-10) and transforming growth factor β (TGF-β) and metabolic reprogramming of tumor cells to create an immune-excluded phenotype (32). The gene discussed is TGFB1; the disease is neoplasm.